# CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 21-196

# **CHEMISTRY REVIEW(S)**



# DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS, HFD-120 REVIEW OF CHEMISTRY, MANUFACTURING, AND CONTROLS

NDA 21-196 **CHEM. REVIEW #5 REVIEW DATE 03-JUN-02 ASSIGNED DATE DOCUMENT DATE CDER DATE SUBMISSION TYPE** 21-MAY-02 16-MAY-02 17-MAY-02 **AMENDMENT** NAME AND ADDRESS OF APPLICANT Orphan Medical, Inc. 13911 Ridgedale Drive, Suite 250 Minnetonka, MN 55305 DRUG PRODUCT NAME Xyrem® oral solution Proprietary: Nonproprietary/USAN [1966]: sodium oxybate Code Name/Number: Chem. Type/Ther. Class: 1P PHARMACOLOGICAL CATEGORY/INDICATION Reduce the incidence of cataplexy and to improve the symptom of daytime sleepiness in patients with narcolepsy **DOSAGE FORM Oral Solution STRENGTHS** 500 mg/mL **ROUTE OF ADMINISTRATION** Oral **DISPENSED** XXX RX OTC \_\_\_ Yes **SPECIAL PRODUCTS** XXX NO CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA Sodium 4-hydroxybutyrate 4-Hydroxybutanoic acid monosodium salt Sodium gamma hydroxybutyrate Mol. Wt. 126.09 C<sub>4</sub>H<sub>7</sub>NaO<sub>3</sub> CAS Registry #: 502-85-2 sodium oxybate SUPPORTING DOCUMENTS: IND ---IND — (Treatment IND) and 12 packaging DMF's **RELATED DOCUMENTS: None CONSULTS: None** REMARKS/COMMENTS: The sponsor has requested a 36-month expiry. The sponsor has submitted updated drug product stability from 6 drug product batches manufactured at and 4 drug product batches All batches were easily within specification. The impurity levels do not increase upon produced at storage at 25°C<sub>i</sub> CONCLUSIONS & RECOMMENDATIONS: The requested tentative expiry of 36 months is acceptable.

cc: Orig. NDA 21-196

HFD-120

HFD-120/TOliver

HFD-120/PM/AMHomonnay

HFD-120/MGuzewska

R/D Init by: MEG

Thomas F. Oliver, Ph.D., Chemist

Filename: n21196.05



\_\_\_\_\_ page(s) have been removed because it contains trade secret and/or confidential information that is not disclosable.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Thomas Oliver 6/3/02 01:44:43 PM CHEMIST

Maryla Guzewska 6/3/02 01:49:00 PM CHEMIST





### NDA 21-196

Xyrem® (sodium oxybate) oral solution

Orphan Medical, Inc.

**Chemistry Review** 

Thomas F. Oliver, Ph.D. HFD-120



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

